Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

AI startup ByteBrain is transforming clinical trials with agent-based optimization, cutting costs, boosting efficiency, and ...

As stakeholders debate fair market value in clinical trial budgeting, a new task force works to align sponsors, CROs, and ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary - a milestone that reflects two ...

Phase II CONFIDENCE study data reveal that simultaneous initiation of Kerendia and Jardiance significantly improves UACR and ...

Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers. Click here ...

Five deals that showcase the potential dealmakers see in the surgical equipment segment. Ampersand Capital, PAI Partners and ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The ...